Compare APP & TMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APP | TMO |
|---|---|---|
| Founded | 2012 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Industrial Machinery/Components |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 101.7B | 255.1B |
| IPO Year | 2021 | 1996 |
| Metric | APP | TMO |
|---|---|---|
| Price | $260.39 | $671.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 33 | 28 |
| Target Price | $480.08 | ★ $690.62 |
| AVG Volume (30 Days) | ★ 3.4M | 2.2M |
| Earning Date | 11-04-2026 | 10-21-2026 |
| Dividend Yield | N/A | ★ 0.28% |
| EPS Growth | ★ 115.23 | 7.32 |
| EPS | 7.32 | ★ 9.10 |
| Revenue | $5,480,717,000.00 | ★ $20,918,000,000.00 |
| Revenue This Year | $47.58 | $7.47 |
| Revenue Next Year | $26.05 | $5.17 |
| P/E Ratio | ★ $36.02 | $74.26 |
| Revenue Growth | ★ 16.38 | 14.47 |
| 52 Week Low | $260.59 | $435.27 |
| 52 Week High | $738.01 | $705.79 |
| Indicator | APP | TMO |
|---|---|---|
| Relative Strength Index (RSI) | 33.48 | 53.19 |
| Support Level | N/A | $635.32 |
| Resistance Level | $336.89 | $694.33 |
| Average True Range (ATR) | 10.60 | 22.47 |
| MACD | 0.18 | -1.29 |
| Stochastic Oscillator | 5.68 | 52.45 |
AppLovin is a vertically integrated advertising technology company that acts as a demand-side platform for advertisers, a supply-side platform for publishers, and an exchange facilitating transactions between the two. About 80% of AppLovin's revenue comes from the DSP, AppDiscovery, while the remainder comes from the SSP, Max. AppLovin's primary tool for future growth is AXON 2, which is an ad optimizer operating within the DSP that allows advertisers to place ads according to specified return thresholds.
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).